{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T18:39:47Z","timestamp":1779907187439,"version":"3.53.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04510-4","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T09:31:54Z","timestamp":1741944714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"7","key":"4510_CR1","first-page":"1580","volume":"13","author":"HUH Virk","year":"2023","unstructured":"Virk HUH, Escobar J, Rodriguez M, Bates ER, Khalid U, Jneid H, Birnbaum Y, Levine GN, Smith SC Jr. Dual antiplatelet therapy: a concise review for clinicians. Life (Basel). 2023;13(7):1580.","journal-title":"Life (Basel)"},{"issue":"5","key":"4510_CR2","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/joa3.13128","volume":"40","author":"Y Saito","year":"2024","unstructured":"Saito Y, Kobayashi Y. Antithrombotic management in atrial fibrillation patients following percutaneous coronary intervention: a clinical review. J Arrhythm. 2024;40(5):1108\u201314.","journal-title":"J Arrhythm"},{"issue":"5","key":"4510_CR3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2020.09.011","volume":"77","author":"DJ Kumbhani","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ, Bhatt DL, Cuker A, Gluckman TJ, Marine JE, Mehran R, Messe SR, Patel NS, Peterson BE, Rosenfield K, Spinler SA, Thourani VH. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(5):629\u201358.","journal-title":"J Am Coll Cardiol"},{"key":"4510_CR4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","volume":"138","author":"DJ Angiolillo","year":"2018","unstructured":"Antithrombotic therapy in, Angiolillo DJ, Goodman SG, Bhatt DL, et al. Patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north American perspective-2018 update. Circulation. 2018;138:527\u201336.","journal-title":"Circulation"},{"key":"4510_CR5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jcin.2021.02.039","volume":"14","author":"D Capodanno","year":"2021","unstructured":"Capodanno D. Triple therapy, dual therapy, and modulation of anticoagulation intensity. JACC Cardiovasc Interv. 2021;14:781\u20134.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"4510_CR6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3390\/jcm13010098","volume":"13","author":"F Gragnano","year":"2023","unstructured":"Gragnano F, Capolongo A, Micari A, Costa F, Garcia-Ruiz V, De Sio V, Terracciano F, Cesaro A, Moscarella E, Coletta S, Raucci P, Fimiani F, De Luca L, Gargiulo G, And\u00f2 G, Calabr\u00f2 P. Antithrombotic therapy optimization in patients with atrial fibrillation undergoing percutaneous coronary intervention. J Clin Med. 2023;13(1):98.","journal-title":"J Clin Med"},{"issue":"16","key":"4510_CR7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, S\u00f8rensen R, Clausen MT, Fog-Petersen ML, Rauns\u00f8 J, Gadsb\u00f8ll N, Gislason GH, Folke F, Andersen SS, Schramm TK, Abildstr\u00f8m SZ, Poulsen HE, K\u00f8ber L, Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433\u201341.","journal-title":"Arch Intern Med"},{"issue":"2","key":"4510_CR8","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1002\/ccd.28535","volume":"96","author":"AE Sullivan","year":"2020","unstructured":"Sullivan AE, Nanna MG, Rao SV, Cantrell S, Gibson CM, Verheugt FWA, Peterson ED, Lopes RD, Alexander JH, Granger CB, Yee MK, Kong DF. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv. 2020;96(2):E102\u20139.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"4510_CR9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jjcc.2009.12.014","volume":"55","author":"Y Uchida","year":"2010","unstructured":"Uchida Y, Mori F, Ogawa H, Takagi A, Hagiwara N. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol. 2010;55(3):362\u20139.","journal-title":"J Cardiol"},{"issue":"10206","key":"4510_CR10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz PE, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335\u201343.","journal-title":"Lancet"},{"issue":"38","key":"4510_CR11","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, Gilard M, Hinterbuchner L, Jankowska EA, J\u00fcni P, Kimura T, Kunadian V, Leosdottir M, Lorusso R, Pedretti RFE, Rigopoulos AG, Rubini Gimenez M, Thiele H, Vranckx P, Wassmann S, Wenger NK, Ibanez B, ESC Scientific Document Group. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"key":"4510_CR12","first-page":"e21810","volume":"14","author":"A Hussain","year":"2022","unstructured":"Hussain A, Minhas A, Sarwar U, Tahir H. Triple antithrombotic therapy (Triple Therapy) after percutaneous coronary intervention in chronic anticoagulation: a literature review. Cureus. 2022;14:e21810.","journal-title":"Cureus"},{"key":"4510_CR13","doi-asserted-by":"crossref","first-page":"132959","DOI":"10.1016\/j.ijcard.2025.132959","volume":"422","author":"A Cesaro","year":"2025","unstructured":"Cesaro A, Acerbo V, Gragnano F, Calabr\u00f2 P. A pragmatic approach for thrombotic prevention after acute coronary syndromes. Int J Cardiol. 2025;422:132959.","journal-title":"Int J Cardiol"},{"issue":"2","key":"4510_CR14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00002018-200932020-00006","volume":"32","author":"AM Hochberg","year":"2009","unstructured":"Hochberg AM, Pearson RK, O\u2019Hara DJ, Reisinger SJ. Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA adverse event reporting system. Drug Saf. 2009;32(2):137\u201346.","journal-title":"Drug Saf"},{"issue":"12","key":"4510_CR15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","volume":"33","author":"HW Wang","year":"2010","unstructured":"Wang HW, Hochberg AM, Pearson RK, Hauben M. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117\u201333.","journal-title":"Drug Saf"},{"issue":"5","key":"4510_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479\u201387.","journal-title":"Drug Saf"},{"issue":"6","key":"4510_CR17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40272-024-00657-3","volume":"26","author":"K Sridharan","year":"2024","unstructured":"Sridharan K, Sivaramakrishnan G. Adverse event profile of first-line drugs for treating patent ductus arteriosus in neonates: a disproportionality analysis study of USFDA adverse event reporting system. Paediatr Drugs. 2024;26(6):767\u201385.","journal-title":"Paediatr Drugs"},{"issue":"2","key":"4510_CR18","doi-asserted-by":"crossref","first-page":"e024537","DOI":"10.1136\/bmjopen-2018-024537","volume":"9","author":"R Phillips","year":"2019","unstructured":"Phillips R, Hazell L, Sauzet O, Cornelius V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open. 2019;9(2):e024537.","journal-title":"BMJ Open"},{"issue":"6","key":"4510_CR19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10741-023-10335-0","volume":"28","author":"V Acerbo","year":"2023","unstructured":"Acerbo V, Cesaro A, Scherillo G, Signore G, Rotolo FP, De Michele G, Scialla F, Raucci G, Panico D, Fimiani F, Moscarella E, Gragnano F, Calabr\u00f2 P. Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease. Heart Fail Rev. 2023;28(6):1325\u201334.","journal-title":"Heart Fail Rev"},{"key":"4510_CR20","unstructured":"MedDRA browser (. August 2018 Version 3.0). Available at: http:\/\/tools.meddra.org (Accessed on 25th October 2024)."},{"issue":"4","key":"4510_CR21","doi-asserted-by":"crossref","first-page":"e081990","DOI":"10.1136\/bmjopen-2023-081990","volume":"14","author":"R Kiguba","year":"2024","unstructured":"Kiguba R, Isabirye G, Mayengo J, Owiny J, Tregunno P, Harrison K, Pirmohamed M, Ndagije HB. Navigating duplication in pharmacovigilance databases: a scoping review. BMJ Open. 2024;14(4):e081990.","journal-title":"BMJ Open"},{"issue":"2","key":"4510_CR22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"issue":"7","key":"4510_CR23","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1111\/bcp.15269","volume":"88","author":"E Raschi","year":"2022","unstructured":"Raschi E, Salvo F, Khouri C. Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: a call to action. Br J Clin Pharmacol. 2022;88(7):3535\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"4510_CR24","unstructured":"Practical aspects of signal detection in pharmacovigilance. Report of CIOMS working group VIII. Geneva. Available at: https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf (Accessed on December 31, 2024)."},{"issue":"6","key":"4510_CR25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, Brueckner A, Candore G, Carnovale C, Crisafulli S, Cutroneo PM, Dolladille C, Drici MD, Faillie JL, Goldman A, Hauben M, Herdeiro MT, Mahaux O, Manlik K, Montastruc F, Noguchi Y, Nor\u00e9n GN, Noseda R, Onakpoya IJ, Pariente A, Poluzzi E, Salem M, Sartori D, Trinh NTH, Tuccori M, van Hunsel F, van Puijenbroek E, Raschi E, Khouri C. The REporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47(6):585\u201399.","journal-title":"Drug Saf"},{"issue":"8","key":"4510_CR26","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.3390\/jcm13082313","volume":"13","author":"CC Kaufmann","year":"2024","unstructured":"Kaufmann CC, Muthspiel M, Lunzer L, Pogran E, Zweiker D, Burger AL, Wojta J, Huber K. Antiplatelet therapy and anticoagulation before, during, and after acute coronary syndrome. J Clin Med. 2024;13(8):2313.","journal-title":"J Clin Med"},{"issue":"16","key":"4510_CR27","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH. AUGUSTUS investigators. Antithrombotic therapy after Acute Coronary syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"4510_CR28","doi-asserted-by":"crossref","first-page":"102449","DOI":"10.1016\/j.rpth.2024.102449","volume":"8","author":"JK Schaefer","year":"2024","unstructured":"Schaefer JK, Errickson J, Kong X, Ali MA, DeCamillo D, Edupuganti S, Haymart B, Kaatz S, Kline-Rogers E, Kozlowski JH, Krol GD, Sood SL, Froehlich JB, Barnes GD. Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study. Res Pract Thromb Haemost. 2024;8(4):102449.","journal-title":"Res Pract Thromb Haemost"},{"issue":"20","key":"4510_CR29","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/CIRCULATIONAHA.120.046534","volume":"141","author":"JH Alexander","year":"2020","unstructured":"Alexander JH, Wojdyla D, Vora AN, Thomas L, Granger CB, Goodman SG, Aronson R, Windecker S, Mehran R, Lopes RD. Risk\/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141(20):1618\u201327.","journal-title":"Circulation"},{"issue":"12","key":"4510_CR30","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.hlc.2022.09.003","volume":"31","author":"C Hammett","year":"2022","unstructured":"Hammett C, Badve SV, Kerr PG, Tran HA, Dundon BK, Lo S, Wong A, Joseph JE, Deague J, Perkovic V. Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease: a review of the evidence with recommendations for Australian clinical practice. Heart Lung Circ. 2022;31(12):1604\u201311.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"4510_CR31","first-page":"151","volume":"20","author":"JP Law","year":"2020","unstructured":"Law JP, Pickup L, Townend JN, Ferro CJ. Anticoagulant strategies for the patient with chronic kidney disease. Clin Med (Lond). 2020;20(2):151\u20135.","journal-title":"Clin Med (Lond)"},{"issue":"10","key":"4510_CR32","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265\u201379.","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"4510_CR33","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","volume":"34","author":"J Oldgren","year":"2013","unstructured":"Oldgren J, Wallentin L, Alexander JH, James S, J\u00f6nelid B, Steg G, Sundstr\u00f6m J. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J. 2013;34(22):1670\u201380.","journal-title":"Eur Heart J"},{"issue":"9","key":"4510_CR34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/ijcp.12863","volume":"70","author":"GY Lip","year":"2016","unstructured":"Lip GY, Pan X, Kamble S, Kawabata H, Mardekian J, Masseria C, Bruno A, Phatak H. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a real-world observational study in the United States. Int J Clin Pract. 2016;70(9):752\u201363.","journal-title":"Int J Clin Pract"},{"key":"4510_CR35","doi-asserted-by":"crossref","unstructured":"Schaefer J, Errickson J, Kong X et al. A comparison of bleeding events among patients on apixaban, rivaroxaban, and warfarin for atrial fibrillation and\/or venous thromboembolism. Abstract 135. Presented at the 65th American Society of Hematology Annual Meeting and Exposition; December 9, 2023; San Diego, California.","DOI":"10.1182\/blood-2023-184457"},{"issue":"4","key":"4510_CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/EBP.0000000000001136","volume":"24","author":"M Schneider","year":"2021","unstructured":"Schneider M, Kim I. Apixaban better than rivaroxaban? Evidence-Based Pract. 2021;24(4):7.","journal-title":"Evidence-Based Pract"},{"key":"4510_CR37","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","volume":"320","author":"WA Ray","year":"2018","unstructured":"Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. 2018;320:2221\u201330.","journal-title":"JAMA"},{"issue":"23","key":"4510_CR38","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","volume":"326","author":"WA Ray","year":"2021","unstructured":"Ray WA, Chung CP, Stein CM, Smalley W, Zimmerman E, Dupont WD, Hung AM, Daugherty JR, Dickson A, Murray KT. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA. 2021;326(23):2395\u2013404.","journal-title":"JAMA"},{"issue":"25","key":"4510_CR39","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, Birmingham M, Ianus J, Burton P, van Eickels M, Korjian S, Daaboul Y, Lip GY, Cohen M, Husted S, Peterson ED, Fox KA. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334.","journal-title":"N Engl J Med"},{"issue":"Suppl C","key":"4510_CR40","doi-asserted-by":"crossref","first-page":"C20","DOI":"10.1093\/eurheartjsupp\/suad034","volume":"25","author":"L De Luca","year":"2023","unstructured":"De Luca L. Low-dose rivaroxaban: can cardiovascular events be reduced? Eur Heart J Suppl. 2023;25(Suppl C):C20\u20136.","journal-title":"Eur Heart J Suppl"},{"key":"4510_CR41","doi-asserted-by":"crossref","unstructured":"Shurrab M, Austin PC, Jackevicius CA, Tu K, Qiu F, Haldenby O, Davies S, Lopes RD, Baykaner T, Johnson LS, Healey JS, Ko DT. Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: a population-based cohort study. Heart Rhythm. 2024;21:S1547\u20135271.","DOI":"10.1016\/j.hrthm.2024.08.033"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04510-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04510-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T09:32:06Z","timestamp":1741944726000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04510-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4510"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04510-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"180"}}